Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT03742544 Enrolling by invitation - Hypertension Clinical Trials

Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy

Start date: June 23, 2015
Phase:
Study type: Observational

Post-marketing surveillance of Telostop TAB (Telmisartan/Rosuvastatin)

NCT ID: NCT03742219 Terminated - Hypertension Clinical Trials

Peru Longitudinal Study

Start date: June 5, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the change in disease prevalence over time in impoverished urban communities in Lima, Peru.

NCT ID: NCT03740074 Completed - Hypertension Clinical Trials

Personal Activity Intelligence (PAI) Pilot

PAI
Start date: October 2, 2018
Phase: N/A
Study type: Interventional

Pilot study to evaluate the use of the Personal Activity Intelligence (PAI) score in a clinical setting.

NCT ID: NCT03739034 Completed - Hypertension Clinical Trials

Evaluation of a Lifestyle Medicine Practice

Start date: June 28, 2018
Phase: N/A
Study type: Interventional

This project will evaluate the success of the PI's lifestyle medicine practice.

NCT ID: NCT03730038 Completed - Dyslipidemias Clinical Trials

Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia

Start date: February 18, 2019
Phase: N/A
Study type: Interventional

Leucine-rich glioma inactivated 3(Lgi3) has been postulated to have a pro-inflammatory adipokine that inter-plays with other adipokines in adipogenesis and metabolic inflammation according to recent investigations. Thus, in this study, we sought to demonstrate that the treatment of statin can decrease Lgi3 level along with the decrease of the atherosclerosis to further evaluate the role of Lgi3 in atherosclerosis.

NCT ID: NCT03728621 Completed - Obesity Clinical Trials

Lifestyle Interventions and Metabolic Profile in Obese Children

Start date: January 2012
Phase: N/A
Study type: Interventional

This study evaluates if promotion of a normocaloric and balanced diet and of physical activity, through an individual- or group-based lifestyle intervention of 12 months, may affect anthropometric measurements and metabolic profile in obese children.

NCT ID: NCT03726866 Recruiting - Hypertension Clinical Trials

A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects

Start date: August 31, 2018
Phase: Phase 1
Study type: Interventional

To evaluate pharmacokinetic properties and drug interactions between D326 and D337 co-administered groups, the CKD-828 alone and the total co-administered groups.

NCT ID: NCT03724825 Completed - Obesity Clinical Trials

Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men

Start date: December 1, 2018
Phase:
Study type: Observational

Obesity is associated with low testosterone in men and with dyslipidemia. Adropin hormone is negatively correlated with body mass index and is associated with dyslipidemia. correlation between adropin and testosterone will be evaluated.

NCT ID: NCT03718286 Completed - Clinical trials for Acute Coronary Syndrome

Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI

EPIC STEMI
Start date: March 11, 2019
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, placebo controlled parallel group clinical trial evaluating the effects of acute treatment with a PCSK9 inhibitor (alirocumab) versus placebo on low-density lipoprotein (LDL) in 100 high-risk patients presenting with STEMI and referred for primary PCI. The objective is to determine the effect of acute, rapid lowering of LDL cholesterol with alirocumab added to high dose statin therapy in patients with STEMI undergoing primary PCI. The hypothesis is that, in patients with STEMI undergoing primary PCI, rapid lowering of LDL cholesterol with a PCSK9 Inhibitor (alirocumab) initiated in the acute setting pre-PCI, will favourably affect LDL cholesterol concentrations compared with placebo.

NCT ID: NCT03707899 Completed - Clinical trials for Hypertension With Dyslipidemia

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers

Start date: December 13, 2018
Phase: Phase 1
Study type: Interventional

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers.